BETA DRUGS is well placed to capitalise on growth opportunities in the oncology drugs segment. It has a healthy Balance Sheet. Average RoE in past three years is 24%. P/E ratio is 15x. Revenue/earnings CAGR of 26%/33% over FY23–26 is expected. TP is Rs 1325
Beta Drugs is one of the leading players in the domestic oncology space
| Subscribe To Our Free Newsletter |
